Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

aTYR PHARMA (ATYR) Enterprise Value (2019 - 2025)

Historic Enterprise Value for aTYR PHARMA (ATYR) over the last 7 years, with Q3 2025 value amounting to -$90.4 million.

  • aTYR PHARMA's Enterprise Value fell 3660.1% to -$90.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$90.4 million, marking a year-over-year decrease of 3660.1%. This contributed to the annual value of -$72.3 million for FY2024, which is 2647.78% up from last year.
  • According to the latest figures from Q3 2025, aTYR PHARMA's Enterprise Value is -$90.4 million, which was down 3660.1% from -$80.5 million recorded in Q2 2025.
  • Over the past 5 years, aTYR PHARMA's Enterprise Value peaked at -$44.2 million during Q2 2021, and registered a low of -$116.5 million during Q3 2021.
  • Moreover, its 5-year median value for Enterprise Value was -$84.7 million (2024), whereas its average is -$85.5 million.
  • Its Enterprise Value has fluctuated over the past 5 years, first plummeted by 23930.62% in 2021, then soared by 3863.59% in 2022.
  • Over the past 5 years, aTYR PHARMA's Enterprise Value (Quarter) stood at -$108.1 million in 2021, then surged by 38.64% to -$66.3 million in 2022, then plummeted by 48.29% to -$98.4 million in 2023, then grew by 26.48% to -$72.3 million in 2024, then dropped by 25.0% to -$90.4 million in 2025.
  • Its Enterprise Value was -$90.4 million in Q3 2025, compared to -$80.5 million in Q2 2025 and -$76.5 million in Q1 2025.